2375240-92-7

2375240-92-7 structure

Name: Efruxifermin
Chemical Name: Efruxifermin
CAS Number: 2375240-92-7
Molecular Formula:
Molecular Weight:
Catalog: Signaling Pathways Protein Tyrosine Kinase/RTK FGFR
Create Date: 2023-02-02 09:46:23
Modify Date: 2024-01-09 23:45:19
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis[1].

Name	Efruxifermin

Description	Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis[1].
Related Catalog	Signaling Pathways >> Protein Tyrosine Kinase/RTK >> FGFR Research Areas >> Metabolic Disease
Target	FGF21
In Vivo	Efruxifermin (0-100 mg/kg，皮下注射，每周一次，持续4或26周)以剂量依赖的方式减少 Sprague Dawley 大鼠的体重增加[1]。 Animal Model: Male and female Sprague Dawley rats[1] Dosage: 0, 1, 10, 30, 100 mg/kg Administration: Subcutaneous injection, Once weekly, for 4 or 26 weeks Result: Significantly reduced body weight gain after 4 and 26 weeks, despite increasing food intake. Markers of sympathetic activation, urinary corticosterone and ratio of adrenal-to-body weight were unchanged.
References	[1]. Tillman EJ, et al. Efruxifermin, a long-acting Fc-fusion FGF21 analogue, reduces body weight gain but does not increase sympathetic tone or urine volume in Sprague Dawley rats. Br J Pharmacol. 2022 Apr;179(7):1384-1394.

No Any Chemical & Physical Properties